Malignant Melanoma Archive - IOZK

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

2023-05-03/in Dendritic Cells, Glioblastoma, International Publications, Malignant Melanoma

A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma

2023-03-07/in Dendritic Cells, International Publications, Malignant Melanoma

Current „state of the art“ on dendritic cell-based cancer vaccines in melanoma

2023-01-09/in Dendritic Cells, International Publications, Malignant Melanoma

Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models

2022-07-07/in Colorectal Cancer, International Publications, Malignant Melanoma, Newcastle Disease Virus

Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.

2021-08-09/in Dendritic Cells, International Publications, Malignant Melanoma

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

2021-08-01/in Dendritic Cells, International Publications, Malignant Melanoma

Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy

2021-07-19/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma

A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma

2021-06-29/in Dendritic Cells, International Publications, Malignant Melanoma

Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

2021-05-19/in Dendritic Cells, International Publications, Malignant Melanoma, Malignant Pleural Mesothelioma

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis

2021-05-12/in Dendritic Cells, International Publications, Malignant Melanoma